Sionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Consensus Price Target of $42.33

Sionna Therapeutics, Inc. (NASDAQ:SION) has been given an average recommendation of “Hold” by the thirteen analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $42.33.

Several equities analysts have recently issued reports on SION shares. Lifesci Capital cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 10th. Stifel Nicolaus lowered Sionna Therapeutics from a “buy” rating to a “hold” rating and set a $7.00 target price on the stock. in a report on Monday, August 10th. Guggenheim cut Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, August 10th. Citigroup lowered shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, August 10th. Finally, BTIG Research downgraded shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 10th.

Sionna Therapeutics Price Performance

NASDAQ SION opened at $3.73 on Monday. The stock’s fifty day moving average price is $5.33 and its 200 day moving average price is $29.57. Sionna Therapeutics has a 1 year low of $3.52 and a 1 year high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.02). Sell-side analysts forecast that Sionna Therapeutics will post -2.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other Sionna Therapeutics news, Director Ra Capital Management, L.P. sold 3,448,811 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $6.33, for a total value of $21,830,973.63. Following the sale, the director directly owned 3,448,812 shares of the company’s stock, valued at approximately $21,830,979.96. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SION. State of Wyoming purchased a new position in shares of Sionna Therapeutics in the second quarter worth about $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Sionna Therapeutics in the 2nd quarter valued at about $44,000. Quantbot Technologies LP purchased a new stake in Sionna Therapeutics in the 2nd quarter valued at about $80,000. Strs Ohio purchased a new position in shares of Sionna Therapeutics in the first quarter valued at approximately $116,000. Finally, AXQ Capital LP acquired a new position in shares of Sionna Therapeutics in the second quarter valued at approximately $202,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disorder that affects the lungs and other organs. The company is working to address the underlying cause of CF by developing small-molecule therapies designed to improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Sionna’s research centers on the nucleotide-binding domain 1 (NBD1) of CFTR, which plays an important role in the protein’s structure and activity.